Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 8/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.68 |
| ▸ | NPC1 | O15118 | 7/20 | 0.68 |
| ▸ | RAB9A | P51151 | 6/20 | 0.68 |
| ▸ | MAPT | P10636 | 4/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.68 |
| ▸ | GAA | P10253 | 2/20 | 0.68 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.68 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.68 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.68 |
| ▸ | JAK2 | O60674 | 1/20 | 0.65 |
| ▸ | JAK1 | P23458 | 1/20 | 0.65 |
| ▸ | TYK2 | P29597 | 1/20 | 0.65 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.62 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.62 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7341264 | 0.89 | TSHR (0.68) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL18290067 | 0.87 | PNLIP (0.67) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL14426572 | 0.86 | RAB9A (0.74) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL467396 | 0.84 | P2RX1 (0.77) | PTGS1TBXAS1MAPK1PTGS2MAPK14 | |
| SCHEMBL14228391 | 0.83 | JAK2 (0.69) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL8316833 | 0.83 | SMN1; SMN2 (0.61) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL2681276 | 0.82 | RAB9A (0.69) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL1753321 | 0.82 | JAK2 (0.68) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL2226570 | 0.82 | JAK2 (0.68) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL678770 | 0.82 | JAK2 (0.68) | MEN1KMT2ANPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| WO-2009016088-A1 | THE USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | WO | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| EP-1638556-B1 | 2-AMINOBENZOTHIAZOLES AS CB1 RECEPTOR INVERSE AGONISTS | HOFFMANN LA ROCHE (CH) | 2008-04-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | GABBR1, GABBR2, CHRM2 | MEN1 1233/4885KMT2A 632/4885NPC1 869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.